Viking Therapeutics, Inc.
VKTXHealthcareNASDAQBiotechnology · Last scanned May 29, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of May 28
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. At a $3.74B market cap, Viking Therapeutics, Inc. ranks as a mid-cap company within healthcare. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Market Cap
$3.74B
Beta
0.71
P/E (TTM)
—
P/E (Fwd)
-7.09
EPS (TTM)
$-4.15
EPS (Fwd)
$-4.54
ROE
-70.0%
ROA
-42.5%
Cash
$603.0M
Total Debt
$0
Free CF
-$177.4M
52W Change
20.1%
Annual Financials
Cash vs Debt
Viking Therapeutics, Inc. reports $603.0M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$177.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -70.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing VKTX.